Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.58 |
| ▸ | NPY4R | P50391 | 9/20 | 0.58 |
| ▸ | NPY1R | P25929 | 8/20 | 0.58 |
| ▸ | NPY2R | P49146 | 6/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 10/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433281 | 0.92 | NPY5R (0.51) | NPY5RNPY4RNPY1RNPY2RNPBWR1 | |
| SCHEMBL31433466 | 0.88 | NPBWR1 (0.51) | NPY5RNPY4RNPY1RNPBWR1 | |
| SCHEMBL7464387 | 0.85 | NPY4R (0.58) | NPY5RNPY4RNPY1RNPY2RNPBWR1 | |
| SCHEMBL31694507 | 0.83 | NPY4R (0.51) | NPY5RNPY4RNPY1RNPY2RNPBWR1 | |
| SCHEMBL31433308 | 0.82 | IL23R (0.50) | NPY4RNPY1RNPY2R | |
| SCHEMBL30445792 | 0.82 | TFPI (0.53) | NPY4RNPY1RNPY2RNPBWR1 | |
| SCHEMBL31114987 | 0.82 | NPY4R (0.56) | NPY5RNPY4RNPY1RNPY2RNPBWR1 | |
| SCHEMBL31114992 | 0.81 | NPY4R (0.64) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL31114991 | 0.81 | NPY4R (0.59) | NPY5RNPY4RNPY1RNPY2RNPBWR1 | |
| SCHEMBL30445796 | 0.81 | BACE1 (0.54) | NPY5RNPY4RNPY1RNPY2RNPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | NPY5R 3645/4885NPY4R 1616/4885NPY1R 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.